Innovation in medicine has led to the development of novel small molecule and biologic formulations that require parenteral administration via intravenous (IV), subcutaneous (SC), intramuscular (IM), or other administration routes via injection. Concurrently, innovative drug delivery systems (e.g., infusion pumps, autoinjectors, wearable infusors, etc.) have also been developed to facilitate patient access to parenteral therapies. Accordingly, the number of novel small molecule and biologic drug products approved for parenteral administration have risen in recent years (Figure 1), including drug products for subcutaneous administration. There were 95 biologic therapies for subcutaneous administration approved by the FDA in 2017 alone and an approximate 240 biologics for subcutaneous administration are in development or in process for approval by the FDA1.